Related Experiment Video

Updated: Feb 27, 2026

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes
07:22

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Published on: March 7, 2025

1.1K

Poor adherence with ACE inhibitors is a risk factor of CVA with oral hypoglycemic agents in diabetic patients

Muhammad Tariq Aftab1, Hasnain Abbas Dharamshi2, Ahmed Faraz2

  • 1College of Medicine, University of Dammam, Dammam, Saudi Arabia.

Pakistan Journal of Pharmaceutical Sciences
|June 27, 2017
PubMed

Insights

Poor adherence to antihypertensive medications increases the risk of cerebrovascular accident (CVA). This is particularly significant for diabetic patients on oral hypoglycemic agents, where non-adherence to ACE inhibitors is a key risk factor for CVA.

Area of Science:

  • Cardiology
  • Neurology
  • Pharmacology

Background:

  • Poor medication adherence significantly impacts pharmacotherapy outcomes, especially for antihypertensive drugs.
  • Antihypertensive medication non-adherence can lead to severe complications like cerebrovascular accident (CVA).

Purpose of the Study:

  • To investigate the association between poor adherence to antihypertensive medications and CVA in both diabetic and non-diabetic patients.
  • To identify specific antihypertensive drug classes associated with CVA risk in patients with hypertension and diabetes.

Main Methods:

  • A study involving 100 CVA patients admitted to a tertiary care hospital.
  • Inclusion criteria: diagnosed CVA, primary hypertension, available therapeutic records, and patient/successor consent.
  • Exclusion criteria: secondary hypertension, newly diagnosed hypertension, and complete medication adherence. Morisky Medication Adherence Scale was used.

Main Results:

  • The study included 100 CVA patients (mean age 62.15 years, 3:1 male to female ratio).
  • 59 patients had both diabetes and hypertension, while 41 had hypertension alone.
  • Poor adherence to ACE inhibitors was significantly associated with CVA in diabetic patients using oral hypoglycemic agents (P<0.05).

Conclusions:

  • Poor adherence to antihypertensive medications, particularly ACE inhibitors, is a significant risk factor for cerebrovascular accident (CVA).
  • This risk is notably elevated in diabetic patients concurrently using oral hypoglycemic agents.
  • Optimizing medication adherence is crucial for preventing CVA in hypertensive and diabetic populations.

More Related Videos

Improving IV Insulin Administration in a Community Hospital12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.4K
Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid06:21

Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid

Published on: April 7, 2023

2.2K

Related Concept Videos

Oral Hypoglycemic Agents: &#945;-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
672
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
758
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
739
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
1.4K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.7K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
786